Logo image of MEDCL.PA

MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis

EPA:MEDCL - Euronext Paris - Matif - FR0004065605 - Common Stock - Currency: EUR

17.46  +0.45 (+2.65%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MEDCL. MEDCL was compared to 52 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MEDCL have multiple concerns. MEDCL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MEDCL had negative earnings in the past year.
In the past year MEDCL had a positive cash flow from operations.
MEDCL had negative earnings in each of the past 5 years.
In the past 5 years MEDCL reported 4 times negative operating cash flow.
MEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFMEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M

1.2 Ratios

MEDCL has a worse Return On Assets (-53.43%) than 82.69% of its industry peers.
Industry RankSector Rank
ROA -53.43%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDCL.PA Yearly ROA, ROE, ROICMEDCL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of MEDCL (91.60%) is better than 92.31% of its industry peers.
The Profit Margin and Operating Margin are not available for MEDCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEDCL.PA Yearly Profit, Operating, Gross MarginsMEDCL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

3

2. Health

2.1 Basic Checks

MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
MEDCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDCL.PA Yearly Shares OutstandingMEDCL.PA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MEDCL.PA Yearly Total Debt VS Total AssetsMEDCL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.36, we must say that MEDCL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.36, MEDCL is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
MEDCL has a debt to FCF ratio of 2.96. This is a good value and a sign of high solvency as MEDCL would need 2.96 years to pay back of all of its debts.
The Debt to FCF ratio of MEDCL (2.96) is better than 67.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.96
Altman-Z 0.36
ROIC/WACCN/A
WACC7.41%
MEDCL.PA Yearly LT Debt VS Equity VS FCFMEDCL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.46 indicates that MEDCL should not have too much problems paying its short term obligations.
MEDCL has a Current ratio (1.46) which is in line with its industry peers.
A Quick Ratio of 1.46 indicates that MEDCL should not have too much problems paying its short term obligations.
MEDCL has a better Quick ratio (1.46) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 1.46
MEDCL.PA Yearly Current Assets VS Current LiabilitesMEDCL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MEDCL have decreased by -6.95% in the last year.
The Revenue has decreased by -1.64% in the past year.
MEDCL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.88% yearly.
EPS 1Y (TTM)-6.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.97%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%23.41%

3.2 Future

The Earnings Per Share is expected to grow by 51.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, MEDCL will show a very strong growth in Revenue. The Revenue will grow by 39.77% on average per year.
EPS Next Y141.86%
EPS Next 2Y102.49%
EPS Next 3Y61.57%
EPS Next 5Y51.25%
Revenue Next Year35.16%
Revenue Next 2Y71.41%
Revenue Next 3Y47.74%
Revenue Next 5Y39.77%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDCL.PA Yearly Revenue VS EstimatesMEDCL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
MEDCL.PA Yearly EPS VS EstimatesMEDCL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MEDCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 58.05, which means the current valuation is very expensive for MEDCL.
Based on the Price/Forward Earnings ratio, MEDCL is valued a bit more expensive than 69.23% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.29, MEDCL is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 58.05
MEDCL.PA Price Earnings VS Forward Price EarningsMEDCL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

The rest of the industry has a similar Price/Free Cash Flow ratio as MEDCL.
Industry RankSector Rank
P/FCF 28.73
EV/EBITDA N/A
MEDCL.PA Per share dataMEDCL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MEDCL's earnings are expected to grow with 61.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y102.49%
EPS Next 3Y61.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MEDCL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDINCELL SA

EPA:MEDCL (8/18/2025, 5:29:50 PM)

17.46

+0.45 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-17 2025-06-17/amc
Earnings (Next)12-09 2025-12-09
Inst Owners29.31%
Inst Owner ChangeN/A
Ins Owners3.53%
Ins Owner ChangeN/A
Market Cap577.58M
Analysts86.25
Price Target23.59 (35.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.9%
PT rev (3m)3.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-26.47%
Revenue NY rev (3m)-26.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 58.05
P/S 54.15
P/FCF 28.73
P/OCF 27
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)0.3
Fwd EY1.72%
FCF(TTM)0.61
FCFY3.48%
OCF(TTM)0.65
OCFY3.7%
SpS0.32
BVpS-1.63
TBVpS-1.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.6%
FCFM 188.48%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.96
Debt/EBITDA N/A
Cap/Depr 76.11%
Cap/Sales 12.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 1.46
Altman-Z 0.36
F-Score5
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.97%
EPS Next Y141.86%
EPS Next 2Y102.49%
EPS Next 3Y61.57%
EPS Next 5Y51.25%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%23.41%
Revenue Next Year35.16%
Revenue Next 2Y71.41%
Revenue Next 3Y47.74%
Revenue Next 5Y39.77%
EBIT growth 1Y9.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year351.1%
EBIT Next 3Y89.72%
EBIT Next 5YN/A
FCF growth 1Y184.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y193.85%
OCF growth 3YN/A
OCF growth 5YN/A